Last reviewed · How we verify
Gaviscon
At a glance
| Generic name | Gaviscon |
|---|---|
| Also known as | natriumalginaat and natriumbicarbonaat, BE386802. |
| Sponsor | Sanofi |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Alginate vs Sucralfate for GERD Symptomatic Relief (PHASE2, PHASE3)
- Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief Study (PHASE3)
- Compound Sodium Alginate Double Action Chewable Tablets 4-hour Esophageal pH Study in GERD Patients (PHASE3)
- The Impact of Adjuvant Liquid Alginate on Endoscopic Ablation Therapy of Complicated Barrett's Esophagus (PHASE2)
- PH Metry Study to Compare the Antacid Activity of Z0063 Versus Gaviscon Double Action Tablets, in Healthy Adult Subjects (PHASE1)
- Scintigraphy Study to Compare the Antireflux Activity of the Z0063 Versus Gaviscon Double Action Tablets, in Healthy Adult Subjects (PHASE1)
- A Comparison of Effectiveness of Oral Sucrolfate, Alginate and Hydrotalcide in Dispeptic Pain Treatment (PHASE4)
- 48 Hours Esophagal pH-monitoring With and Without Gaviscon (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gaviscon CI brief — competitive landscape report
- Gaviscon updates RSS · CI watch RSS
- Sanofi portfolio CI